Financial Tearsheet

Company Overview

ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.

ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.

Recent Financial News

IR Contacts

Gregory FCA

Joe Hassett
484-686-6600
joeh@gregoryfca.com
https://www.gregoryfca.com/

Stock Performance

Today's Open 0.9000
Volume 175,792
Day Range 0.8705 - 0.9651
52 Week Range 0.5990 - 2.2500
Bid/Ask 0.8869 / 0.8935
Bid/Ask Size 200 X 700
Previous Close 0.8900
Market Cap 12.96 million
Shares Outstanding 14.5 million
Dividend/Yield 0.0000 / 0.0000%
EPS (TTM) -2.255100
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
May 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 26, 2020 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 13, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 08, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Francois Michelon, Chief Executive Officer and Chairman

Michael Thornton, Chief Technology Officer

David Wells, Chief Financial Officer

Amy Sitzler, Vice President of Engineering and Programs

Steve Freeman, Human Resources Leader

Renaud Maloberti, Chief Commercial Officer

Board of Directors

Francois Michelon, Chairman of the Board

Louis Basenese, Director

Anthony DiGiandomenico, Director

Sanjiv Sam Gambhir, M.D., Ph.D., Director

Michael Harsh, Director

Alexander Tokman, Director